

Department of Planning and Budget 2015 Fiscal Impact Statement

1. Bill Number: SB1380

House of Origin	<input type="checkbox"/> Introduced	<input type="checkbox"/> Substitute	<input type="checkbox"/> Engrossed
Second House	<input type="checkbox"/> In Committee	<input type="checkbox"/> Substitute	<input checked="" type="checkbox"/> Enrolled

2. Patron: Obenshain

3. Committee: Passed Both Houses.

4. Title: Schedule I drugs.

5. Summary: Schedule I drugs. Adds N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)indazole-3-carboxamide (other name: AB-CHMINACA), N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)indazole-3-carboxamide (other name: 5-fluoro-AMB), and 3,4-methylenedioxy-N,N-dimethylcathinone (other names: Dimethylone, bk-MDDMA) to Schedule I of the Drug Control Act, in accordance with the action of the Board of Pharmacy adding these substances to Schedule I pursuant to § 54.1-3443.

6. Budget Amendment Necessary: No.

7. Fiscal Impact Estimates: FINAL.

8. Fiscal Implications: The Board of Pharmacy has already added the three compounds specified in the proposal to Schedule I of the Drug Control Act. The bill is not expected to have any additional impact on bed space for state prisons or state police. However, bed space needs of the Department of Juvenile Justice cannot be determined.

9. Specific Agency or Political Subdivisions Affected: Department of Health Professions, Department of State Police, and the Department of Juvenile Justice.

10. Technical Amendment Necessary: No.

11. Other Comments: HB 1564, introduced by Delegate Garrett, is a companion bill.